National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 29770 [05-10327]
Download as PDF
29770
Federal Register / Vol. 70, No. 99 / Tuesday, May 24, 2005 / Notices
the latent infected cells from the
uninfected cells; (2) even when
antiretroviral drugs are able to
completely suppress detectable HIV
replication, these latent infected cells
will remain and HIV can subsequently
complete the viral replication cycle to
produce more virus. Since proteosome
inhibitors can activate lytic replication
from latent infected cells, proteosome
inhibitors may lead to therapies in
which proteosome inhibitors are given
together with highly active antiretroviral
therapy in an effort to decrease or
eliminate the reservoir of latent infected
cells with hope of perhaps eventually
curing a patient of HIV infection.
Treatment of Human Viral Infections
(Imatinib)
Drs. Steven Zeichner and Vyjayanthi
Krishnan (NCI).
U.S. Provisional Application No. 60/
588,015 filed 13 Jul 2004 (DHHS
Reference No. E–281–2004/0–US–01).
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
This application describes the
methods for treating or preventing a HIV
infection by the administration of ablkinase inhibitor called imatinib and its
derivatives. Several available agents can
inhibit HIV replication by targeting one
or another viral protein, such as the
viral reverse transcriptase, protease,
envelope fusion process, or integrase, or
by targeting the interaction of a viral
component with a host cell component,
for example the host cell viral receptor
or co-receptor. However, HIV can
readily become resistant to these drugs,
and new therapeutic approaches for HIV
infection are needed. The studies
described in the application show that
the expression of many host cell genes
changes in response to HIV replication,
and show that targeting one of these
changes with imatinib can inhibit viral
replication. Thus targeting the host cell,
and making the host cell less hospitable
to the virus can inhibit viral replication.
The application thus describes a new
agent that inhibits viral replication by
acting on the host cell, which may offer
new approaches to therapy for HIV
infection. These approaches may be less
likely to engender rapid resistance in
the virus to the therapy.
Treatment of Human Viral Infections
(Farnesyl Transferase Inhibitors)
Drs. Steven Zeichner and Vyjayanthi
Krishnan (NCI).
U.S. Provisional Application No. 60/
587,771 filed 13 Jul 2004 (DHHS
Reference No. E–282–2004/0–US–01).
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
VerDate jul<14>2003
17:36 May 23, 2005
Jkt 205001
This application describes the
methods for treating or preventing an
HIV infection by the administration of
farnesyl transferase inhibitors such as
FTI277, L–744832, BMS214662,
R115777 and SCH66336. It has been
known that HIV, once it infects a cell,
integrates into the cellular genome and
can (1) rapidly undergo lytic infection,
or (2) lay dormant for a period of time
(latent infection). The existence of latent
infected cells poses a great challenge to
HIV therapy because (1) there are no
good existing means that can separate
the latent infected cells from the
uninfected cells; (2) even when
antiretroviral drugs are able to
completely suppress detectable HIV
replication, these latent infected cells
will remain and HIV can subsequently
complete the viral replication cycle to
produce more virus. Since farnesyl
transferase inhibitors can activate lytic
replication from latent infected cells by
modulating membrane-bound Ras-Rho
levels, farnesyl transferase inhibitors
may lead to therapies in which farnesyl
transferase inhibitor is given together
with highly active antiretroviral therapy
in an effort to decrease or eliminate the
reservoir of latent infected cells with
hope of perhaps eventually curing a
patient of HIV infection.
Dated: May 17, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–10316 Filed 5–23–05; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Frm 00056
Fmt 4703
Dated: May 16, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–10327 Filed 5–23–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Meeting
BILLING CODE 4140–01–P
PO 00000
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Review of Research Projects (Cooperative
Agreements) U01s.
Date: May 27, 2005.
Time: 9 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Valerie L. Prenger, PhD,
Health Scientist Administrator, Review
Branch, Room 7214, Division of Extramural
Affairs, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, MSC 7924,
Bethesda, MD 20892–7924, (301) 435–0270,
prengerv@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Sfmt 4703
Notice is hereby given of a Conference
on Research Training Initiatives,
sponsored by the National Institute of
Dental and Craniofacial Research
(NIDCR).
The conference will be open to the
public as indicated below, with
attendance limited to space available.
This meeting will also be made
available by video cast at
https://videocast.nih.gov/.
Conference Name: Research Training
Initiatives.
Date: June 9, 2005.
Open: 8:30 a.m. to 5 p.m.
Agenda: The conference will focus on
a variety of issues relating to research
training. A significant portion of the
meeting will be devoted to discussion of
training of both clinician scientists and
basic scientists, from building a
pipeline, through undergraduate,
graduate and postgraduate research
training culminating in bridging to
scientific independence.
E:\FR\FM\24MYN1.SGM
24MYN1
Agencies
[Federal Register Volume 70, Number 99 (Tuesday, May 24, 2005)]
[Notices]
[Page 29770]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-10327]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel Review of Research Projects (Cooperative
Agreements) U01s.
Date: May 27, 2005.
Time: 9 a.m. to 11 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Valerie L. Prenger, PhD, Health Scientist
Administrator, Review Branch, Room 7214, Division of Extramural
Affairs, National Heart, Lung, and Blood Institute, 6701 Rockledge
Drive, MSC 7924, Bethesda, MD 20892-7924, (301) 435-0270,
prengerv@nhlbi.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: May 16, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-10327 Filed 5-23-05; 8:45 am]
BILLING CODE 4140-01-M